The company manufactures and markets a variety of pharmaceutical formulations, including dry powder injections, tablets, and syrups, primarily serving institutional government tenders and international markets from its facilities in Baddi.
The company operates in a highly fragmented generic drug market with heavy reliance on government tenders, which is reflected in negative net margins and poor returns on capital. There is no evidence of brand power or cost advantage, as the company has struggled to pass on rising material costs, leading to persistent losses.
Management has aggressively expanded capacity and acquired a subsidiary through the insolvency process, yet these investments have failed to generate positive returns, resulting in a deteriorating debt-to-equity ratio and negative interest coverage.
The company's aggressive capacity expansion and distressed acquisitions, funded by high-interest debt, proved fatal as the generic drug market remained a commodity trap. By 2029, the inability to service debt or meet statutory obligations led to a total liquidity freeze, while the lack of pricing power ensured that revenue growth only accelerated losses. The persistent failure to deposit employee benefits and taxes eventually triggered severe regulatory crackdowns, resulting in a complete loss of institutional trust and a forced liquidation at pennies on the dollar.
RichFakir rates ANG Lifesciences India Ltd's business quality as poor — 6/100 on our quality score (profitability, growth, balance-sheet strength and capital allocation). We assess its competitive moat as none.
On our model, ANG Lifesciences India Ltd is trading about 31% below our estimate of fair value; we rate its price cheap. This is an educational estimate from public filings, not a recommendation.
RichFakir's educational verdict on ANG Lifesciences India Ltd is: Avoid. We are steering clear of this one — the red flags below outweigh anything the price or numbers offer.
RichFakir's educational estimate of ANG Lifesciences India Ltd's fair value is about ₹47 per share, derived from public filings. It's our estimate for research — not a price target or a recommendation to buy or sell.
View the full live analysis →